Insights on Digital Health Technology Survey 2016

EBOOK 

<strong>Insights</strong> on Digital 

Health Technology 

Survey 2016: 

How Digital Health Devices and Data 

Impact Clinical Trials 

Industry’s Leading Digital Health Platform

Table of Contents 

01 Executive Summary 

09 Selecting the Right Endpoint 

02 Key Findings 

10 Bringing in the Benefits 

03 Demographics 

04 The Role of Digital Health 

Technologies in Clinical Trials 

04 Digital Data: From Mobile 

Apps to Wearables 

12 Clinical Outcomes: Which 

Therapeutic Areas Offer the 

Biggest Impacts 

13 The Challenges of Digital Health 

15 Summary and Conclusions 

06 The Role of Digital 

Health Technologies 

16 References 

07 The Business Drivers 

Behind Digital Health 

EBOOK 

<strong>Insights</strong> on Digital Health Technology Survey 2016: How Digital Health Devices and Data Impact Clinical Trials

Executive Summary 

The digital health revolution—aided by the growth in connectivity, the 

global availability of smartphones and the decreasing size of sensors to 

make wearables smaller and more discrete—has provided drug developers 

access to a wealth of real-world, participant-generated data that 

is enabling better insights and streamlined clinical trial processes. 

Developing drugs is a challenging process. Only around one in 10 

drugs in Phase 1 actually make it through to the market. 1 This high 

attrition rate is one factor contributing to the high costs of drug development. 

According to the Tufts University Center for the Study of Drug 

Development, developing a drug from bench to market costs an estimated 

$2.6 billion. 2 

Late-stage clinical trials make up a large portion of those costs, as they 

involve larger numbers of patients and can run for longer durations of 

time. This means recruitment and retention of patients and the collection 

of high quality data is absolutely vital. 

In clinical trials, patients are carefully selected to meet ultra-specific 

criteria and their adherence to the treatment regimen is closely monitored. 

This is not the case outside of trials in the real world, where life 

gets in the way and people are all shapes and sizes, doses are missed 

and other conditions can exacerbate disease progression. 

Due to these variables, real-world outcomes may not reflect those 

seen during study conduct. In light of this reality, regulators, payers and 

providers are increasingly demanding real-world data that demonstrates 

the efficacy of the drug in the everyday world. 

Against that backdrop, Validic conducted a survey of the BioPharma 

Dive readership, including 166 biopharma and life sciences industry 

researchers, executives and technology/software professionals to 

provide insight into the benefits and challenges of using digital health 

data and devices in clinical trials. 

EBOOK <strong>Insights</strong> on Digital Health Technology Survey 2016: How Digital Health Devices and Data Impact Clinical Trials 1

Key Findings 

1. The use of digital technologies is growing: Over 60 percent of 

survey respondents stated they have used digital health technologies 

in clinical trials and an impressive 97.4 percent plan to use 

digital technologies more in clinical trials in the next five years. 

2. Applications are moving from mobile apps to wearables: The most 

commonly used devices in clinical trials currently are mobile apps 

and in-home clinical grade devices. Future use is likely to focus more 

on wearable activity trackers and sensors. This maps to increased 

use of these types of devices by consumers. Less than 3 percent 

stated they would not use devices and digital data in the future. 

3. The roles of digital data are changing: Currently, the use of digital 

health technologies is mostly focused on recruitment, remote patient 

monitoring and medication adherence. There is some use in postmarket 

research and fostering patient communities. One hundred 

percent of respondents saw technology as improving medication 

adherence. Patient communities are expected to be one of the 

biggest growth areas. 

4. Business is driving digital health: Three of the biggest drivers 

selected by respondents—reducing trial costs, streamlining trial 

processes and demonstrating real-world efficacy—are all driven by 

the bottom line: cutting drug development costs and ensuring an 

adequate return on investment. Patient-centricity, the increased focus 

on the patient experience, is also a key driver. 

5. Finding the right endpoint is key: More than two thirds of individuals 

surveyed thought improving medication adherence was the most 

important outcome for drug developers, as patient recruitment and 

retention are challenges across clinical development. 

Real-time information, flagged by over half 

of respondents as one of the top benefits of 

digital data, supports early decision-making in 

drug development. 

6. Real-time data access is an important benefit: Real-time information, 

flagged by over half of respondents as one of the top benefits 

of digital data, supports early decision-making in drug development. 

This frees up drug developers and sites to monitor the responses of 

patients more closely. 

7. Chronic disease remains important: Chronic conditions, particularly 

cardiovascular disease and metabolic disorders, are a focus 

for many pharma and biotech companies because of the size of the 

market and the increasing aging population. Seven in 10 of those 

surveyed thought digital health data could have the greatest impact 

in improving care for chronic disease populations. 

8. Challenges remain: The use of digital data and devices in clinical 

trials is still relatively new. Respondents were most concerned about 

the accuracy of data generated by digital health devices. 


Demographics 

The survey received responses from 166 people. Over 40 percent 

of respondents were from pharma and biotech companies, with the 

remaining responses coming from contract research organizations and 

technology and software providers. 

Because of the specialized skill set needed to source and analyze 

digital data, many companies are outsourcing this part of the drug 

development process. These results reflect the Cutting Edge 

Information 2015 survey that found that around 70% of companies 

were outsourcing their data capture, and about half were outsourcing 

its analysis. 3 

70% 

60% 

50% 

40% 

30% 

20% 

10% 

0 

64% 

North 

America 

What is your region of operations? 

23% 

Global 

5% 3% 3% 3% 

Central and 

Eastern Europe 

Asia 

Western 

Europe 

Central or 

South America 

What kind of company do you work for? 

57% 43% 

CRO, TECH 

PROVIDER, 

OTHER 

What is your role with the company? 

31% Executive leadership 

23% Clinical operations 

15% Innovation 

13% Sales 

10% Marketing 

08% IT 

PHARMA/ 

BIOTECH 


The Role of Digital Health Technologies in 

Clinical Trials 

As technology becomes more accessible and affordable, the role of 

digital health data is growing in clinical trials. As of September 2015, 

there were at least 299 clinical trials using wearables, according to 

Bloomberg. 3 Supporting that increased prevalence, two thirds of survey 

respondents have already used digital health technologies in clinical 

trials, and almost all expect to increase their use within the next 5 years. 

Digital Data: From Mobile Apps to Wearables 

Mobile apps and in-home clinical-grade devices were used most 

commonly in clinical trials, closely followed by wearable activity trackers 

and sensors. 

Mobile apps, which are downloaded to tablets or smartphones, are 

likely to be accepted by trial participants given higher levels of familiarity 

with apps. In 2015, almost two thirds of people in the U.S. owned 

a smartphone and almost half owned a tablet. 4,5 Health-related apps on 

smartphones are also very popular. 

Do you plan to utilize digital 

health technologies more over 

the next 5 years? 

Have you used digital 

technologies in clinical trials? 

97% 

YES 

3% 

NO 

64% 

YES 

36% 

NO 


In a survey conducted in June 2015, 58 percent of smartphone users 

had downloaded a health-related app, and 41 percent had downloaded 

more than 5 apps. These included diet and physical activity trackers and 

apps that help people to learn exercises. 6 

In-home clinical grade devices, such as heart rate, blood pressure and 

blood sugar monitors, can provide teams running clinical trials with 

accurate and reliable data. If these devices are connected via Wi-Fi or 

Bluetooth, this data can be accessed in real time. 

However, the vast majority of clinical devices are not currently 

Bluetooth-enabled. New technology leveraging optical character 

recognition (OCR), such as Validic’s VitalSnap, can help overcome this 

100% 

80% 

60% 

40% 

20% 

0 

What kinds of digital technologies have you included or 

would like to include in trials? Select all that apply. 

67% 

33% 

Wearable 

activity 

trackers 

Would like to include in future trials 

55% 

45% 

In-home clinicalgrade 

devices 

(glucometer, 

blood pressure 

cuff, etc.) 

64% 

36% 

Sensors 

(injectable 

sensors, 

sensor-enabled 

pill bottles, 

syringes etc.) 

Have included in trials 

53% 

47% 

Mobile apps 

75% 

25% 

I have not 

used digital 

technologies 

in trials 

This technology gives researchers the ability 

to integrate digital health data from the 

non-connected devices that are already 

clinically validated and being used in the trial. 

challenge. It enables users to capture health data from non-connected 

medical devices via their smartphone’s camera, and the data are automatically 

transferred to the clinician. This technology gives researchers 

the ability to integrate digital health data from the non-connected 

devices that are already clinically validated and being used in the trial. 

Wearable activity trackers, which are already used in trials by around 

a fifth of respondents, can range from those similar to the consumer-grade 

devices to sophisticated, FDA Class II accelerometers. 

Wearables can be as small and as unobtrusive as a Band-Aid. MC10’s 

tiny adhesive biostamp, for example, incorporates flexible circuits, 

allowing for size reductions to the point the wearer hardly feels it. 3 The 

presence of such trackers can also trigger reminders to be sent to 

patients to take drugs as required by the study. 

Respondents were enthusiastic about the growing use of devices, 

with only a small number saying that they would not use devices in the 


future. While the use of in-home clinical grade devices and mobile apps 

looks stable, the growth is expected to be in wearable activity trackers 

and in sensors. 

To be effective, and to ensure that people continue to use them, any 

digital devices must be easy to learn and use, particularly for the senior 

population, who are most likely to have chronic conditions. Things to 

take into account include font size, color, size and shape of buttons, 

size of screens and the user’s experience of technology. This could 

also include incorporating the technology into something that is already 

familiar, such as a watch, clothing or contact lenses. It is important, 

though, not to make assumptions about the senior population and their 

use of technology – in 2015, 30 percent of Americans ages 65 or older 

owned smartphones, 55 percent owned a computer and 32 percent 

owned a tablet. 5 

Providing a benefit to the user will also increase effectiveness. 

Supplying patients with feedback on disease status or reminders to take 

medications, as well as ways to access information and education about 

the drug and/or illness, can increase engagement with digital health 

devices, creating a positive feedback loop. 

The Role of Digital Health Technologies 

Currently, the use of digital health technologies is mostly focused on 

recruitment, remote patient monitoring and medication adherence, with 

some use in post-market research and fostering patient communities. 

Patient recruitment for clinical trials can be challenging, particularly 

in rare diseases where the communities of patients are small. Using 

digital communication and analysis of digital health data can allow 

researchers to find the individuals for their clinical trials and widen the 

trial’s geographic reach. Contract research organizations may also have 

their own repositories of patients who have already been involved in 

past trials and who may be willing to take part again. This speeds up 

recruitment and allows prescreening for specific inclusion and exclusion 

criteria. An example of this is Quintiles’ ‘Digital Patient Unit.’ 7 

100% 

Have you used or would you like to use digital technologies 

for the following applications? Select all that apply. 

Would like to use 

Have used 

80% 

60% 

54% 

57% 

68% 

61% 

74% 

In 2015, 30% of Americans ages 65 or older 

owned smartphones, 55% owned a computer 

and 32% owned a tablet. 

40% 

20% 

0 

46% 

Subject 

recruitment 

43% 

Remote 

patient 

monitoring 

32% 

Post-market 

research 

39% 

Medication 

adherence 

26% 

Patient 

communities 


These communities also support long-term follow-up, which feeds 

into post-market research. Other sources of post-market digital health 

data include analysis of electronic medical records to track physicians’ 

prescribing patterns. 

The Business Drivers Behind Digital Health 

The cost of drug development continues to escalate, meaning the 

market prices of innovative drugs, particularly biologics, are often very 

high. As a result of this, payers, providers and consumers want proof of 

the value and cost effectiveness. If payers and consumers have to pay 

a high price, they want confirmation that the drug does what the developer 

says, both in clinical trials and in the real world. This need for a 

demonstration of efficacy and real-world value is one of the key drivers 

behind the implementation of digital health. 

Clinical trials are costly. In order to ensure a return on investment and 

an ability to invest in future research and development, companies are 

continually trying to reduce trial costs and streamline trial processes. 

Respondents to the survey selected these as key drivers for uptake of 

digital health. 

By automating the collection of data through digital health devices and 

apps, researchers have access to more accurate and objective data, 

and quicker. This allows companies to focus clinical trial staff on more 

productive parts of projects, such as patient support or data analysis. 

Improving the collection of data streamlines clinical trial processes, ultimately 

helping to get drugs to market quicker. 

What of the following are the key business 

drivers for using digital health at your 

company? Select all that apply. 

73% 

68% 

Demonstrate efficacy and realworld 

value 

Reduce trial costs 

68% Patient-centricity 

59% 

46% 

35% 

Streamline trial processes 

Precision medicine 

Competitive differentiator 


Remote data collection from digital health devices has the potential 

to reduce the number of site visits, which lowers the need to provide 

transport or reimburse travel costs. It also lightens the burden of clinical 

trial involvement for patients, as they won’t need to spend as much 

time traveling or miss other commitments, such as work, as often. This 

contributes to the patient-centricity of the study—another key driver 

highlighted in this survey. 

Personalized or precision medicine 

is increasingly becoming part of 

everyday treatment. 

Patient-centric clinical trials can also be achieved by listening and 

responding to patients within digital communities, from patient forums 

to Twitter and Facebook. While the analysis of this kind of free text data 

is challenging, it helps companies to understand what patients’ unmet 

needs are, and what will help them to stay compliant. Data mining 

and analytics companies can monitor these kinds of conversations 

and carry out analyses that provide companies with better insight. 8 

Patient-reported outcomes, where patients are encouraged to enter 

their own data and contribute to endpoints that are more relevant to 

their everyday experiences, could help improve patient engagement, 

although questions remain about accuracy. 

Personalized or precision medicine is increasingly becoming part of 

everyday treatment, as more targeted drugs move through clinical trials 

and onto the market. Investment into personalized medicine is also 

growing, headlined by President Barack Obama’s national Precision 

Medicine Initiative. 8 

Access to digital health data is helping pharma companies develop 

targeted medicines by increasing their understanding of who their 

target patients are and helping them access small subgroups of 

patients. Digital health devices also allow researchers to run what are 

effectively one person clinical trials, where information from a lot of n=1 

studies is collated and aggregated, potentially identifying treatment 

97% of respondents believe that digital 

technology will improve clinical trial 

cost effectiveness. 


egimens for subsets of patients, or supporting development of drugs 

for rare diseases. 8 

Almost all of the respondents felt that digital health technology could 

improve the cost-effectiveness of clinical trials. 

Selecting the Right Endpoint 

Digital health devices and sensors can collect a variety of different types 

of data. One of the most challenging parts of clinical trials is ensuring 

patients adhere to trial protocols. This includes taking the drug at the 

right time (morning, afternoon, evening), under the right conditions 

(before or after meals) and at the right intervals and number of doses 

(one tablet three times daily, or three tablets once daily). Reflecting that 

reality, medication adherence was the most commonly chosen endpoint 

respondents wished to measure with digital health technologies. 

Consumer grade activity trackers, such as Fitbit and Garmin, are 

commonly used by people who want to monitor their own health and 

activity levels. But these consumer grade devices are increasingly 

being used in clinical trials as well. As of June 2016, there were 104 

completed, current or pending Fitbit studies in the ClinicalTrials.gov 

website, including studies in obesity, diabetes and cancer. 

Due to user-friendly designs and features, including paired apps, 

these activity trackers tend to be more appealing to consumers, which 

increases the likelihood of long-term usage of and engagement with 

the device. Many activity trackers can also monitor sleep and heart rate, 

and some can also monitor blood pressure, which are all endpoints that 

between 51 percent and 59 percent of respondents felt were important. 

What endpoints would you like to measure 

with digital health technologies? Select all 

that apply. 

72% Medication 

adherence 

oximetry 

39% Pulse 

67% Activity 

59% Heart rate 

54% Blood 

pressure 

51% Sleep 

46% Glucose 

33% Weight 

28% Breathing 

28% Temperature 

23% Nutrition 

23% Spirometry 

10% Smoking 


Blood glucose is an important measure for people with both Type 1 

and Type 2 diabetes, and its tracking is important in studies both in 

treatment and prevention. There are a number of digital health devices 

that can record data on blood glucose for home and clinical trial use, 

allowing monitoring that can help assess outcomes and provide feedback 

for patients, especially those using insulin. Between a third and a 

quarter of respondents were interested in data on breathing, spirometry, 

nutrition and weight. 

Bringing in the Benefits 

Around half of the respondents picked real-time information as the 

most important benefit of digital health data. Getting real-time results 

from a clinical trial provides visibility into how the trial is progressing and 

flags any problems. This can allow early interventions (if allowed by the 

trial protocol). 

Just under 25 percent of respondents felt digital data helped identify 

early signs of disease progression. Iterative or adaptive clinical trials 

allow modification of the parameters of the study based on observations 

allowing for changes to dose or timing, the recruitment of different 

populations, or an early halt to a trial due to success or failure. 

Access to real-time data will help inform these kinds of decisions. 

Knowing when to stop a trial early is also important in more traditional 

randomized controlled trials as well, as it reduces the risk of harm to 

patients. This kind of data also allows companies to make rapid go/ 

no-go decisions about whether to continue development of a drug, 

which saves R&D money and allows selection of a subsequent drug 

candidate to proceed more quickly. This early decision-making was 

seen as a benefit by more than one in 10 respondents. 

What are the 3 most important benefits of 

digital data? 

49% 

39% 

36% 

Real-time information 

Automated and objective 

data collection 

Remote monitoring 

There are a number of digital health devices 

that can record data on blood glucose for 

home and clinical trial use, allowing monitoring 

that can help assess outcomes and provide 

feedback for patients, especially those 

using insulin. 


Digital health devices, providing real-world insights and allowing the 

collection of previously unattainable real-world data, can also help 

support the development of pragmatic clinical trials. These evaluate 

the effectiveness of interventions in conditions more like the real world, 

not so much if and how a treatment works, but whether it works in 

everyday use. 9 

The automation of data collection was chosen as an important benefit 

by almost 40 percent of respondents. Being able to collect data automatically 

and continuously reduces errors in transcription by either the 

clinical trial staff or the patient and lowers the workload of both groups. 

Automated data collection also helps people who have cognitive 

or physical impairments that inhibit their ability to manually record 

outcomes. Real-world and pragmatic studies can be expensive. But 

the cost saving benefits of digital health data, such as the automated 

data collection and remote monitoring could potentially offset these 

higher costs. 

Remote monitoring also opens up clinical trials to patients who otherwise 

would not be able to take part, because they live too far from 

clinical trial centers, or who have physical, visual or cognitive impairments 

that mean they struggle with transport. This is reflected by the 

quarter of participants who selected ‘reduced office visits for participants’ 

as an important benefit to digital health adoption. 

100% 

80% 

60% 

40% 

20% 

0 

Have you seen a return on investment for 

your use of digital health data? 

67% 

It is still too 

early to tell 

23% 

Yes 

10% 

I’m not using 

digital health 

technologies 

Remote monitoring also opens up clinical trials 

to patients who otherwise would not be able 

to take part. 

0% 

No 

Despite the apparent (and realized) benefits, it is still relatively early 

days for many companies in the world of digital health data. While a 

quarter of respondents have seen a return on investment, two thirds 

have stated that it is still too early to tell, which is largely due to the fact 

that digital health technologies haven’t been used in trials very long and 

drug development cycles are on average 10 years. On a more positive 

note, no respondents answered ‘no’ to the question, Have you seen a 

return on investment for your use of digital health data? 


As well as saving money, another route to improving return on investment, 

or at least covering additional costs, is using a digital health 

device or app as part of value-added services post launch. These can 

improve coverage by payers or providers by improving the cost-effectiveness 

of a particular drug, as well as driving better adherence, 

resulting in ongoing income from repeat prescriptions. 

Digital health devices have an obvious role 

to play in clinical trials of chronic disease as 

they can monitor changes over long periods 

of time. 

Clinical Outcomes: Which Therapeutic Areas Offer 

the Biggest Impacts 

Digital health devices have an obvious role to play in clinical trials of 

chronic disease as they can monitor changes over long periods of time. 

This is reflected in the finding that almost three-quarters of respondents 

selected chronic conditions as one of the areas where digital health 

will make the biggest impact. It also reflects the prevalence of chronic 

diseases in the U.S., which affect around half of all adults in the U.S. and 

are behind seven of the 10 leading causes of death. Around 86 percent 

of the healthcare spend in the U.S. is on chronic disease. Rising levels 

of these types of conditions is one of the drivers behind the ongoing 

increases in direct and indirect health costs. 10 

The predominance and significance of chronic disease is also exhibited 

in the selection of cardiovascular disease by almost two thirds of 

respondents and metabolic diseases by over half. CNS disorders were 

selected as a key therapeutic area by half of the respondents, while one 

in three selected oncology. 

Aging populations mean an increase in cognitive diseases such as 

Alzheimer’s disease and other forms of dementia. In response, more 

companies are conducting clinical trials to look at therapeutics that can 

treat or reverse cognitive decline. Wearables and remote monitoring 

Digital health devices also play a role in clinical 

studies for prevention of chronic disease. 


will play an important role in providing data from people whose age and 

cognitive deficits would otherwise make participation difficult. 

Digital health devices also play a role in clinical studies for prevention 

of chronic disease, for example lifestyle factors such as diet and lack of 

exercise that increase the risk of obesity, diabetes and cancer. 

On the other hand, a third of respondents selected acute conditions 

as an area which could benefit from greater adoption of digital health. 

Data generated from digital devices could be particularly helpful for 

proving the value of some of the newer curative therapies for serious 

infections by recording outcomes over longer periods. As an example, 

Gilead’s antiviral, Solvadi (sofosbuvir), hit the headlines because of its 

$84,000 price tag when it was approved by the U.S. Food and Drug 

Administration. Sovaldi is a potentially curative treatment for hepatitis 

C, effective in around 90 percent of cases. According to data from the 

PwC Health Research Institute, while the initial cost is indeed high, the 

savings over the patient’s lifetime due to better health should easily 

offset the high costs. 11 

The Challenges of Digital Health 

The use of digital health data and devices in clinical trials is still relatively 

new, and drug developers have concerns about the challenges these 

new technologies will bring. Chief among respondents’ concerns was 

data accuracy. Looking at rank order, with 1 being the top concern, the 

greatest concern is the accuracy of data. This is frequently a worry for 

new technologies and is one which should be alleviated as technology 

improves. 

In which therapeutic areas will digital health be 

most impactful? Select all that apply. 

73% 

63% 

53% 

47% 

34% 

34% 

Chronic conditions 

Cardiovascular disease 

Metabolic disorders 

CNS disorders including 

Alzheimer’s disease 

Acute conditions 

Rare diseases 

32% Oncology 

21% 

Musculoskeletal disorders 


Digital health is growing fast, and there are many device manufacturers 

working in the space. This makes it difficult to discern which technologies 

are most appropriate for the clinical trial setting. The responses to 

the survey reflect this confusion. 

Once data has been collected, it is important to know whether it is standardized 

and can be integrated into clinical trial platforms and systems. 

Otherwise, the data is either impossible to use or costly to analyze. 

Physicians can be reluctant to use digital 

health devices, feeling inundated with pitches 

to use this app for that drug or one device 

for another study. This could hinder wider 

adoption of digital technologies. 

1 

Accuracy of data 

2 

Standardization 

of data 

3 

How to analyze 

the data in a 

meaningful way 

What are the key concerns you have when it comes to using 

digital health data? (Rank order, 1 being the top concern.) 

4 

Knowing what device 

to use 

5 

Integrating data from 

devices into your 

clinical trial platform 

or system 

6 

Patients’ ability and 

willingness to use 

digital health devices 

9 

21 CRF Part 11 

compliance 

7 

Physicians’ ability and 

willingness to use 

digital health devices 

8 

Lack of guidance 

from the FDA on 

devices 

10 

I’m afraid digital health 

data will demonstrate 

negative results for the 

drug or therapy 

11 

I’m afraid the FDA will 

reject trials results 

that include digital 

health data 


Physicians can be reluctant to use digital health devices, feeling inundated 

with pitches to use this app for that drug or one device for 

another study. This could hinder wider adoption of digital technologies. 

Companies should therefore emphasize ease of use for digital health 

tools, incorporating benefits for the physician as well as the patient. 

Summary and Conclusions 

Advances in digital health devices and data could allow drug developers 

to carry out more detailed and real time analyses of data from 

clinical trials. This has the potential to increase the speed at which drugs 

progress through clinical trials, as well as accelerating decision-making 

by companies on which programs to pursue. While digital health 

remains new, with attendant concerns about how the resulting data can 

be used, there is significant optimism over how a digital revolution could 

transform drug development. 

Advances in digital health devices and data 

could allow pharma and biotech companies to 

carry out more detailed and real time analyses 

of data from clinical trials. 


References 

1 

Hay M, Thomas DW, Craighead JL, et al., Clinical development success rates for investigational 

drugs. Nat Biotechnol2014. 32(1): p. 40-51. 10.1038/nbt.2786. 

2 

DiMasi JA, Grabowski HG,Hansen RW, Innovation in the pharmaceutical industry: New estimates 

of R&D costs. J Health Econ 2016. 47: p. 20-33. 10.1016/j.jhealeco.2016.01.012. 

3 

Edney A,Chen C. Big Pharma Hands Out Fitbits to Collect Better Personal Data. Bloomberg, 

14 September 2015. Available from: http://www.bloomberg.com/news/articles/2015-09-14/ 

big-pharma-hands-out-fitbits-to-collect-better-personal-data. 

4 

Smith A. U.S. Smartphone Use in 2015. PewResearchCenter, 1 April 2015. Available from: http:// 

www.pewinternet.org/2015/04/01/us-smartphone-use-in-2015/. 

5 

Anderson M. The Demographics of Device Ownership. PewResearchCenter, 29 October 2015. 

Available from: http://www.pewinternet.org/2015/10/29/the-demographics-of-device-ownership/. 

6 

Pai A. Survey: 58 percent of smartphone users have downloaded a fitness or health app. 

MobiHealthNews, 5 November 2015. Available from: http://mobihealthnews.com/48273/ 

survey-58-percent-of-smartphone-users-have-downloaded-a-fitness-or-health-app. 

7 

Sharma NS, Patient centric approach for clinical trials: Current trend and new opportunities. 

Perspect Clin Res2015. 6(3): p. 134-8. 10.4103/2229-3485.159936. 

8 

Schork NJ, Personalized medicine: Time for one-person trials.Nature 2015. 520(7549): p. 609-11. 

10.1038/520609a. 

9 

Patsopoulos NA, A pragmatic view on pragmatic trials. Dialogues Clin Neurosci 2011. 13(2): p. 

217-24. 

10 

Kvedar JC, Fogel AL, Elenko E, et al., Digital medicine’s march on chronic disease. Nat Biotechnol 

2016.34(3): p. 239-46. 10.1038/nbt.3495. 

11 

LaMattina J, Forgotten In The Sovaldi Price Debate: Hep-C Patients And Healthcare Savings. 

Forbes 2014. 


Validic provides the industry’s leading 

digital health platform connecting 

pharmaceutical companies, providers, 

payers, wellness companies and healthcare 

IT vendors to patient-generated health data 

from hundreds of in-home clinical devices, 

wearables, and sensors applications. 

Reaching more than 223 million lives in 50 

countries, its scalable, cloud-based solution 

offers one connection to a continuously 

expanding ecosystem of consumer 

and clinical health data, delivering the 

standardized and actionable insights 

needed to drive better outcomes and 

streamline clinical trial processes including 

remote patient monitoring, recruitment 

and pre-clinical and post-marketing 

research. Validic was named to Gartner’s 

“Cool Vendors” list and received Frost & 

Sullivan’s “Best Practices and Best Value in 

Healthcare Information Interoperability” and 

“Top 10 Healthcare Disruptor” awards. 

Are you ready to get up to speed on digital 

health and explore the impact it can have 

on your trials and initiatives? To learn more, 

contact us at hello@validic.com or visit 

www.validic.com. 

LEARN MORE 

@validic 

hello@validic.com

Insights on Digital Health Technology Survey 2016

Create successful ePaper yourself

Delete template?

Save as template?